

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

CAL-120

RRID:CVCL_1104

Type: Cell Line

Proper Citation

RRID:CVCL_1104

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1104

Proper Citation: RRID:CVCL_1104

Description: Cell line CAL-120 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast carcinoma

Defining Citation: [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30613774](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CAL-120

Synonyms: CAL 120, CAL120

Cross References: CLO:CLO_0002179, EFO:EFO_0005356, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-6647, BioGRID_ORCS_Cell_line:166, BioSample:SAMN03472991, BioSample:SAMN03473555, BioSample:SAMN10989564, cancercellines:CVCL_1104, Cell_Model_Passport:SIDM00940, ChEMBL-Cells:ChEMBL3308577, ChEMBL-Targets:ChEMBL1075405, Cosmic:906826,

Cosmic:1995355, Cosmic:2164984, Cosmic-CLP:906826, DepMap:ACH-000212, DSMZ:ACC-459, DSMZCellDive:ACC-459, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906826, GEO:GSM274647, GEO:GSM274665, GEO:GSM344361, GEO:GSM344411, GEO:GSM783963, GEO:GSM827160, GEO:GSM843483, GEO:GSM847210, GEO:GSM847455, GEO:GSM886904, GEO:GSM887969, GEO:GSM1172944, GEO:GSM1669645, IARC_TP53:21208, LiGeA:CCLE_802, LINCS_HMS:51110, LINCS_LDP:LCL-1463, PharmacDB:CAL120_165_2019, PRIDE:PXD030304, Progenetix:CVCL_1104, PubChem_Cell_line:CVCL_1104, SLKBase:3487, Wikidata:Q54808384

ID: CVCL_1104

Record Creation Time: 20220427T215438+0000

Record Last Update: 20260829T231745+0000

Ratings and Alerts

No rating or validation information has been found for CAL-120.

No alerts have been found for CAL-120.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. Cancer research communications, 5(3), 458.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer research communications, 5(2), 375.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Frontiers in oncology, 15, 1549282.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Thatikonda V, et al. (2024) Genetic dependencies associated with transcription factor activities in human cancer cell lines. Cell reports, 43(5), 114175.

Ackermann T, et al. (2024) Breast cancer secretes anti-ferroptotic MUFAs and depends on selenoprotein synthesis for metastasis. *EMBO molecular medicine*, 16(11), 2749.

Paulson AL, et al. (2024) Discovery, Validation and Mechanistic Study of XPO1 Inhibition in the Treatment of Triple-Negative Breast Cancer. *Cancers*, 16(23).

K??ferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. *Cell reports*, 39(2), 110636.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Liu Y, et al. (2020) Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. *Cell chemical biology*, 27(10), 1229.

Johnstone CN, et al. (2020) FGF13 promotes metastasis of triple-negative breast cancer. *International journal of cancer*, 147(1), 230.

Yomtoubian S, et al. (2020) Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. *Cell reports*, 30(3), 755.

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1), 66.

Oberlick EM, et al. (2019) Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. *Cell reports*, 28(9), 2331.

Wu Q, et al. (2019) A chemical toolbox for the study of bromodomains and epigenetic signaling. *Nature communications*, 10(1), 1915.

Hafner M, et al. (2019) Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. *Cell chemical biology*, 26(8), 1067.

Heijink AM, et al. (2019) Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. *Cell reports*, 28(9), 2345.

Zwang Y, et al. (2017) Synergistic interactions with PI3K inhibition that induce apoptosis. *eLife*, 6.

Muir A, et al. (2017) Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. *eLife*, 6.

Malek M, et al. (2017) PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. *Molecular cell*, 68(3), 566.